Codeine Linctus is a licensed, single-constituent oral liquid pharmaceutical preparation formulated as an opioid antitussive (manufactured across the United Kingdom by licensed generic and proprietary suppliers such as Pinewood Laboratories, Thornton & Ross \/ Care, Bells Healthcare, and Galpharm). Chemically designated as $(5R,6S,9R,13S,14R)\\text{-3-methoxy-17-methyl-4,5-epoxymorphin-6-ol phosphate hemihydrate}$<\/span>, codeine phosphate is a naturally occurring or semi-synthetic phenanthrene alkaloid functioning primarily as an in vivo metabolic prodrug to morphine. Structurally, it consists of a pentacyclic morphinan skeleton featuring an ether (furan) bridge between carbon-4 and carbon-5, an aromatic A-ring with a methoxy moiety at carbon-3, a cyclohexenol C-ring with an allylic hydroxyl at carbon-6, and a tertiary $N$<\/span>-methylated bridge at position 17. The carbon-3 methoxy group significantly diminishes its direct binding affinity for human opioid receptors relative to morphine. Its empirical molecular formula as the hemihydrate phosphate salt is $\\text{C}_{18}\\text{H}_{21}\\text{NO}_3\\cdot\\text{H}_3\\text{PO}_4\\cdot\\frac{1}{2}\\text{H}_2\\text{O}$<\/span>, with an average molecular weight of $406.4\\text{ g\/mol}$<\/span> (unconjugated codeine base: $299.36\\text{ g\/mol}$<\/span>).<\/p>\n Standard pharmaceutical presentations of Codeine Linctus in the UK consist of a clear, viscous, pale-straw or yellowish syrup delivering $15\\text{ mg}$<\/span> of codeine phosphate per $5\\text{ mL}$<\/span><\/b> of oral solution ($3\\text{ mg\/mL}$<\/span>). Standard presentations are supplied in amber glass or polyethylene terephthalate (PET) dispensing bottles of $200\\text{ mL}$<\/span><\/b> (delivering a cumulative dose of $600\\text{ mg}$<\/span> of codeine phosphate<\/b>) and $500\\text{ mL}$<\/span><\/b> stock bottles (delivering $1,500\\text{ mg}$<\/span><\/b>). Standard non-active pharmaceutical excipients include a concentrated sucrose syrup vehicle (delivering a substantial glycemic load), liquid glucose, glycerol (E422), ethanol ($96\\%$<\/span>), sodium benzoate (E211), citric acid monohydrate (E330), and purified water (sugar-free variants substitute sucrose and liquid glucose with sorbitol and hydroxyethylcellulose).<\/p>\n Within the United Kingdom regulatory framework:<\/p>\n Historic Pharmacy (P) Status and POM Reclassification:<\/b> Historically, Codeine Linctus ($15\\text{ mg}\/5\\text{ mL}$<\/span>) was classified as a Pharmacy (P) medicine, legally available over the counter under the supervision of a registered community pharmacist. Following escalating evidence of organized pharmacy diversion, rapid physical dependence, and widespread recreational abuse:<\/p>\n The Medicines and Healthcare products Regulatory Agency (MHRA) executed a definitive regulatory intervention in February 2024, reclassifying all oral codeine linctus preparations as Prescription Only Medicines (POM)<\/b>.<\/p>\n<\/li>\n Over-the-counter retail distribution is completely prohibited across the United Kingdom. Supply is legally restricted strictly to dispensing against a valid prescription issued by an authorized prescriber.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Controlled Drug Scheduling:<\/b> Under the Misuse of Drugs Act 1971, codeine is a Class B controlled substance<\/b>. Under the Misuse of Drugs Regulations 2001, standard dilute compound codeine linctus formulations sit within Schedule 5 (CD Inv POM)<\/b>, which legally exempts them from statutory Safe Custody register-logging requirements, but leaves them subject to all baseline POM and Class B unlawful possession, supply, and importation penalties.<\/p>\n<\/li>\n NHS Formulary Positioning:<\/b> Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff; however, routine prescription across NHS Integrated Care Boards (ICBs) is actively discouraged due to clinical consensus deeming opioid antitussives high-risk and largely obsolete.<\/p>\n<\/li>\n<\/ul>\n In clinical toxicology and forensic drug monitoring, Codeine Linctus represents the primary domestic liquid vehicle diverted for the recreational preparation of “lean,” “purple drank,” or “dirty sprite.”<\/b> Bottles diverted from legitimate supply chains command substantial illicit market premiums. This demand drives a parallel illicit market of counterfeit bottles filled with generic cough syrups adulterated with illicitly manufactured designer benzodiazepines (e.g., bromazolam) or high-potency synthetic nitazene opioids<\/b> (e.g., protonitazene, metonitazene, isotonitazene), presenting extreme risks of unexpected, fatal central respiratory arrest.<\/p>\n The pharmacodynamic profile of Codeine Linctus is defined by its role as an in vivo metabolic prodrug, producing central antitussive, sedative, analgesic, and respiratory-depressant effects through converted morphine:<\/p>\n The Prodrug Paradigm and CYP2D6 Bioactivation:<\/b><\/p>\n Unaltered codeine ($3\\text{-O-methylmorphine}$<\/span>) displays exceptionally low intrinsic affinity for human $\\mu$<\/span>-opioid receptors (approximately $200\\text{-fold}$<\/span> to $300\\text{-fold}$<\/span> lower affinity than morphine), exhibiting negligible direct agonist efficacy at physiological concentrations.<\/p>\n<\/li>\n Clinical pharmacological efficacy depends fundamentally on hepatic Phase I $O$<\/span>-demethylation catalyzed by the polymorphic cytochrome P450 isoenzyme CYP2D6<\/b>, which bioactivates approximately $5\\text{ to }10\\%$<\/span> of an ingested dose into free morphine<\/b>. Converted morphine drives the vast majority of its central effects.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Central Medullary Antitussive Suppression:<\/b><\/p>\n Codeine blunts the cough reflex through direct depressant action within the nucleus tractus solitarii (NTS)<\/b> of the medulla oblongata:<\/p>\n<\/li>\n Converted morphine binds to medullary $\\mu$<\/span>-opioid receptors, while parent codeine also interacts with central $\\sigma_1$<\/span>-receptors.<\/p>\n<\/li>\n This raises the threshold of the sensory vagal cough center to afferent mechanical and chemical irritation, suppressing efferent motor signaling directed to the diaphragm, pharynx, and intercostal musculature.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Postsynaptic $\\mu$<\/span>-Opioid (MOP) Receptor Signal Transduction:<\/b><\/p>\n Converted morphine acts as a full agonist at human $\\mu$<\/span>-opioid receptors located across the brainstem, periaqueductal gray (PAG), thalamus, and dorsal horn of the spinal cord:<\/p>\n<\/li>\n Receptor binding activates coupled heterotrimeric inhibitory $G_{\\alpha i\/o}$<\/span> proteins.<\/p>\n<\/li>\n The dissociated $G_{\\alpha}$<\/span> subunit inhibits adenylyl cyclase, lowering intracellular cyclic adenosine monophosphate (cAMP).<\/p>\n<\/li>\n Concurrently, the $G_{\\beta\\gamma}$<\/span> dimer inhibits presynaptic voltage-gated N-type calcium ($Ca^{2+}$<\/span>) channels, arresting the vesicular exocytosis of primary excitatory neurotransmitters (substance P, calcitonin gene-related peptide [CGRP], and L-glutamate).<\/p>\n<\/li>\n Simultaneously, it activates postsynaptic G-protein-coupled inwardly rectifying potassium (GIRK) channels, driving cellular potassium ion efflux. The resulting membrane hyperpolarization stabilizes resting membrane potentials below firing thresholds, dampening ascending sensory transmission.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Respiratory and Enteric Depression:<\/b><\/p>\n Activation of $\\mu$<\/span>-opioid receptors within the pontomedullary respiratory pacemakers (pre-B\u00f6tzinger complex<\/b>) blunts the sensitivity of central chemoreceptors to arterial carbon dioxide tension ($\\text{PaCO}_2$<\/span>) and hypoxia, resulting in dose-dependent central respiratory depression<\/b>.<\/p>\n<\/li>\n In the gastrointestinal tract, stimulation of myenteric $\\mu$<\/span>-receptors inhibits propulsive peristalsis and secretomotor fluid transport while increasing sphincter tone, driving profound constipation<\/b>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Where formally authorized in the United Kingdom, Codeine Linctus possesses an exceptionally narrow, specialized licensed therapeutic scope:<\/p>\n Symptomatic Relief of Dry, Non-Productive Cough (Adults $\\ge 18$<\/span> Years):<\/b><\/p>\n Indicated for the short-term symptomatic relief of distressing, non-productive dry cough in adults aged 18 years and older when non-opioid alternatives have failed.<\/p>\n<\/li>\n Standard Adult Dosing:<\/i> $5\\text{ to }10\\text{ mL}$<\/span> ($15\\text{ to }30\\text{ mg}$<\/span> codeine phosphate)<\/b> taken orally three to four times daily as clinically indicated.<\/p>\n<\/li>\n Ceiling Dosing:<\/i> A maximum single dose of $10\\text{ mL}$<\/span> ($30\\text{ mg}$<\/span>) and a maximum cumulative daily ceiling of $40\\text{ mL}$<\/span> ($120\\text{ mg}$<\/span> codeine phosphate)<\/b> in any 24-hour period.<\/p>\n<\/li>\n Duration Limit:<\/i> Prescriptions must not exceed 3 to 5 days<\/b>. If cough paroxysms persist, thorough clinical re-evaluation is required to exclude underlying malignant, infectious, or asthmatic pulmonary disease.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Strict Contraindication in Paediatrics (<18 Years):<\/b><\/p>\n In compliance with MHRA directives and European Medicines Agency (EMA) safety referrals, all codeine-containing cough and cold medications are strictly contraindicated in children and adolescents under 18 years of age<\/b>. This restriction was mandated following fatal cases of respiratory arrest in pediatric patients who were post-mortem identified as CYP2D6 ultra-rapid metabolizers.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n National Institute for Health and Care Excellence (NICE) guidelines and Clinical Knowledge Summaries (CKS: Cough<\/i>) explicitly advise against the routine prescription of codeine-containing cough suppressants for acute cough<\/b>. Systematic reviews confirm that evidence of superior clinical efficacy over non-opioid demulcents is negligible, whereas the risks of rapid physical tolerance, dependence, fatal accidental overdose, and respiratory compromise are substantial. First-line clinical interventions prioritize non-pharmacological demulcents (e.g., honey and lemon mixtures or glycerol-based non-medicated linctuses).<\/p>\n In non-medical, recreational drug subcultures:<\/p>\n “Lean” \/ “Purple Drank” Misuse:<\/b> Recreational users mix substantial volumes of Codeine Linctus ($50\\text{ to }200\\text{ mL}$<\/span>, delivering $150\\text{ to }600\\text{ mg}$<\/span> of codeine phosphate) into sweetened carbonated beverages, co-ingesting it with first-generation sedating antihistamines (principally promethazine)<\/b>. Promethazine prevents codeine-induced nausea, blocks peripheral histamine-induced itching, and amplifies central sedative-dissociative euphoria.<\/p>\n<\/li>\n Opioid Self-Medication:<\/b> Misused by individuals with underlying opioid use disorders (OUD) to suppress the distressing autonomic storms and myalgias of acute opioid withdrawal.<\/p>\n<\/li>\n<\/ul>\n The pharmacokinetic behavior of Codeine Linctus is characterized by rapid liquid gastrointestinal absorption, extensive first-pass hepatic biotransformation, parallel metabolic pathways, and critical CYP2D6 pharmacogenetic polymorphism<\/b>:<\/p>\n Glucuronidation (Major Route, $\\sim 70\\text{ to }80\\%$<\/span>):<\/b> Direct Phase II conjugation catalyzed by UDP-glucuronosyltransferase UGT2B7<\/b> converts codeine to codeine-6-glucuronide (C6G)<\/b>. C6G possesses modest intrinsic $\\mu$<\/span>-opioid receptor affinity and contributes partially to systemic analgesia and sedation.<\/p>\n<\/li>\n $O$<\/span>-Demethylation via CYP2D6 (Bioactivation Route, $\\sim 5\\text{ to }10\\%$<\/span>):<\/b> Cytochrome P450 2D6 cleaves the 3-methoxy ether group to generate active free morphine<\/b>. Converted morphine is subsequently conjugated by UGT2B7 into active morphine-6-glucuronide (M6G)<\/b> and neurotoxic morphine-3-glucuronide (M3G)<\/b>.<\/p>\n<\/li>\n $N$<\/span>-Demethylation via CYP3A4 ($\\sim 10\\%$<\/span>):<\/b> CYP3A4 mediates $N$<\/span>-demethylation to yield norcodeine<\/b>, an inactive metabolite that undergoes subsequent glucuronidation.<\/p>\n<\/li>\n<\/ol>\n Poor Metabolisers (PMs; $7\\text{ to }10\\%$<\/span> of Caucasian cohorts):<\/b> Individuals possessing two non-functional CYP2D6 alleles (e.g., *3, *4, *5, *6<\/i>). PMs lack the enzymatic capacity to bioactivate codeine into morphine; they experience negligible antitussive or euphoric effects<\/b>, yet remain fully susceptible to codeine-induced constipation, nausea, and histamine release.<\/p>\n<\/li>\n Extensive (Normal) Metabolisers (EMs):<\/b> Display standard therapeutic conversion of codeine to morphine.<\/p>\n<\/li>\n Ultra-Rapid Metabolisers (UMs; up to $10\\%$<\/span> of Caucasians, up to $29\\%$<\/span> of specific North African, Middle Eastern, and Mediterranean populations):<\/b> Individuals harboring gene duplications or amplifications of functional CYP2D6 alleles (e.g., *1xN, *2xN<\/i>). UMs clear codeine rapidly into massive concentrations of circulating free morphine. In UMs, standard therapeutic doses ($15\\text{ to }30\\text{ mg}$<\/span>) can precipitate catastrophic, unexpected central respiratory depression, profound comatose stupor, and fatal apnea<\/b>.<\/p>\n<\/li>\n<\/ul>\n Therapeutic administration of Codeine Linctus suppresses cough paroxysms and induces mild sedation. In supratherapeutic, recreational, or chronic exposure, multi-system toxicities emerge:<\/p>\n Histaminergic Reactions (Very Common, $\\ge 1\/10$<\/span>):<\/b><\/p>\n Codeine acts as a direct, non-immunological secretagogue triggering cutaneous and systemic mast cell degranulation. Ingestion of therapeutic or recreational doses drives acute systemic histamine release, presenting as intense generalized pruritus (itching)<\/b>, cutaneous facial flushing, urticaria, conjunctival injection, and bronchospasm (hazardous in asthmatics).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Gastrointestinal and Autonomic Disruptions (Very Common to Common, $\\ge 1\/100$<\/span> to $\\ge 1\/10$<\/span>):<\/b><\/p>\n Profound Constipation:<\/b> Enteric $\\mu$<\/span>-opioid receptor activation inhibits propulsive peristalsis, increases internal anal sphincter tone, and blunts secretomotor fluid transport, risking severe fecal impaction or stercoral ulceration in chronic users.<\/p>\n<\/li>\n Nausea and vomiting: Direct chemical stimulation of dopamine $D_2$<\/span> and $\\mu$<\/span>-opioid receptors in the chemoreceptor trigger zone (CTZ) of the area postrema.<\/p>\n<\/li>\n Xerostomia (dry mouth) and epigastric discomfort.<\/p>\n<\/li>\n Sphincter of Oddi Spasm:<\/b> Marked constriction of biliary and pancreatic sphincters elevates intrabiliary pressure, precipitating acute biliary colic or exacerbating pancreatitis.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Central Nervous System and Neuropsychiatric Toxicity (Common):<\/b><\/p>\n Drowsiness, daytime somnolence, lightheadedness, dizziness, and cognitive clouding.<\/p>\n<\/li>\n Euphoria (reinforcing psychological dependence) or paradoxical dysphoria, restlessness, and anxiety.<\/p>\n<\/li>\n Confusion and visual hallucinations (disproportionately observed in elderly patients).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe, Emergent and Life-Threatening Hazards:<\/b><\/p>\n Fatal Central Respiratory Depression:<\/b> The primary cause of death in codeine poisoning. Blunting of the brainstem pre-B\u00f6tzinger complex results in severe bradypnea ($<8\\text{ breaths\/min}$<\/span>), progressive cyanosis, stupor advancing to deep unarousable coma, hypercapnic acidosis, and fatal hypoxic cardiac arrest.<\/p>\n<\/li>\n Synergistic Depressant Collapse (“Lean” Toxicity):<\/b> Co-ingestion of Codeine Linctus alongside alcohol, benzodiazepines, or sedating antihistamines (e.g., promethazine)<\/b> synergistically suppresses pontine and medullary respiratory drive, exponentially increasing fatal poisoning rates.<\/p>\n<\/li>\n\n
\n
2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
\n
\n
\n
\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
\n
\n
Clinical Positioning and NICE Guidance<\/h3>\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n\n
\n Pharmacokinetic Parameter<\/strong><\/td>\n Value \/ Metric<\/strong><\/td>\n Clinical Interpretation<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Oral Bioavailability<\/b><\/span><\/td>\n $\\sim 40\\text{ to }70\\%$<\/span><\/b><\/span><\/td>\n Moderate; limited by first-pass hepatic extraction.<\/span><\/td>\n<\/tr>\n \n Time to Peak Concentration ($T_{max}$<\/span>)<\/b><\/span><\/td>\n $30\\text{ to }60\\text{ minutes}$<\/span><\/b><\/span><\/td>\n Liquid form accelerates absorption; rapid onset of central effects.<\/span><\/td>\n<\/tr>\n \n Volume of Distribution ($V_d$<\/span>)<\/b><\/span><\/td>\n $\\sim 3.0\\text{ to }3.5\\text{ L\/kg}$<\/span><\/b><\/span><\/td>\n Extensive tissue distribution; readily crosses the blood-brain barrier.<\/span><\/td>\n<\/tr>\n \n Plasma Protein Binding<\/b><\/span><\/td>\n $\\sim 7\\text{ to }25\\%$<\/span> (Low)<\/b><\/span><\/td>\n Circulates predominantly as free, unbound active drug.<\/span><\/td>\n<\/tr>\n \n Primary Hepatic Enzymes<\/b><\/span><\/td>\n UGT2B7<\/b> ($70\\text{\u2013}80\\%$<\/span>), CYP2D6<\/b> ($5\\text{\u2013}10\\%$<\/span>), CYP3A4<\/span><\/td>\n Complex parallel Phase I oxidation and Phase II glucuronidation.<\/span><\/td>\n<\/tr>\n \n Active Metabolites<\/b><\/span><\/td>\n Morphine<\/b>, Morphine-6-glucuronide (M6G), Codeine-6-glucuronide (C6G)<\/span><\/td>\n Morphine drives the dominant clinical $\\mu$<\/span>-opioid actions.<\/span><\/td>\n<\/tr>\n \n Elimination Route<\/b><\/span><\/td>\n Renal ($85\\text{ to }90\\%$<\/span>, primarily as glucuronides)<\/span><\/td>\n Less than $10\\%$<\/span> excreted unchanged; accumulates in severe renal failure.<\/span><\/td>\n<\/tr>\n \n Elimination Half-Life ($t_{1\/2}$<\/span>)<\/b><\/span><\/td>\n $2.5\\text{ to }3.5\\text{ hours}$<\/span><\/b><\/span><\/td>\n Short half-life necessitates 4- to 6-hourly dosing for therapeutic effect.<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Hepatic Metabolic Pathways<\/h3>\n
\n
The CYP2D6 Pharmacogenetic Dynamic<\/h3>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n